Develop targeted bacteriophage therapeutics. Focus on antibiotic-resistant infections. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 40.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 8% of them.
Analysts' average target sits 179% above today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 64% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $4.9M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 10 buys and 2 sells. Management buying with its own money is usually read as a good sign.
A loss of $173.8M against $4.9M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, ARMP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ARMP is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (8/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.